Verdatum solutions Lady Gaga either tightlyintegrate with the law

Verdatum solutions analyzes Lady Gaga either tightlyintegrate lady gaga cds shows with the law firm's document management system or operate as astand-alone solution with the integrated document tracking system. Thecompany is headquartered in New York, NY and serves law firms in the USand Canada. Its management has over 50 years combined experience in legalpractice, law firm management, and legal IT administration. The companycounts as customers law firms ranging in size from 10 attorneys to over600.

It has been named the 2008 Gold Award Winner in the Dictation Systemscategory by Law Technology News lady gaga twitter . To learn more, visit the company'swebsite Contact:Judy SliwoskiVerdatum888-211-9990Email ContactCopyright 2009, Market Wire, All rights reserved.-0- lady gaga tickets . Bioheart Announces Plans to Launch Clinical Trials in Europe and the USA forSecond-generation Cell Therapy for Treating Advanced Heart FailureSUNRISE, Fla., Jan 12, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc lady gaga concerts . (Nasdaq:BHRT)announced today that it plans to conduct clinical trials for itssecond-generation MyoCell SDF-1 myogenic cell composition for treating advancedheart failure lady gaga cd .

The company believes that it may be able to fund these trials toa large extent with grant funding, which will be non-dilutive to the company'sinvestors lady gaga the view . Earlier this year, Bioheart approached the National Heart, Lung andBlood Institute of the National Institutes of Health to discuss the possibilityof their Cardiovascular Cell Therapy Research Network Centers to participate inthese new clinical trials.MyoCell SDF-1 is a composition of myogenic stem cells derived from a patient'sown thigh muscle that has been modified to over express the SDF-1 protein lady gaga tour . Theproduct candidate is prepared with an 18-step proprietary method in Bioheart'scGMP laboratories lady gaga albums . Utilizing a needle-tipped catheter inserted into the groin ofa patient who is suffering from heart failure, the cells are injected into thescar tissue that has formed in the patient's heart lady gaga show . The goal of MyoCell SDF-1 isto grow new contractile muscle within the scar tissue that will have the abilityto release additional beneficial proteins to assist in the tissue repair processand improve the patient's heart function, exercise capacity and quality of life.In animal studies, MyoCell SDF-1 provided a 54 percent improvement of heartfunction compared to 27 percent for the original MyoCell composition while theplacebo control treated animals declined by 10 percent.The company filed an IND application with the FDA last year and is nearcompleting the additional studies suggested by the FDA to move the MyoCell SDF-1into clinical trials in the USA The U.S. trial is expected to begin this year.After completing a 15-patient dose escalation safety protocol study withone-month follow-up, the company hopes to transition this second-generationproduct into its FDA-authorized Phase II/III MARVEL study, currently active at35 centers in the USA.

MyoCell SDF-1 is substantially similar to the originalMyoCell composition that has been active in clinical trials since early 2001 atmore than 50 centers worldwide . The company has also begun the appropriateregulatory filings to initiate MyoCell SDF-1 clinical studies in Europe andother foreign countries lady gaga music . This quarter, the company has filed or will be filingin Switzerland, the Netherlands, Italy, Belgium, Singapore, Brazil and Korea.Bioheart expects a new state-of-the-art cGMP cell culture facility in Seoul,Korea, with capacity to culture more than 1,800 patients a month, to be up andrunning in 1Q 2009 lady gaga album . This facility, 18% owned by Bioheart, was designed by NNEPharmaplan, Denmark, is heralded as the most advanced cell culture and biologicsmanufacturing operation in the world . This facility will be additive toBioheart's cGMP facility at its headquarters in Sunrise, Florida, and to thecontract facility in Maastricht, the Netherlands, which Bioheart has engagedwith Pharmacell."All the data gathered over many years supports moving the MyoCell SDF-1composition to clinical trials at this time to serve advanced heart failurepatients who are facing worse than 50 percent risk of death within three years,"said Dr. Marc Penn, Medtronic Bakken Chair of Research, Cleveland Clinic. "Thesepatients desperately need something better, and this composition has a chance tobe it.""Bioheart is committed to continuous improvement of our products and services,"said Howard J Leonhardt, chairman, CEO and CTO of Bioheart.